The L/N-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2

Journal of International Medical Research

Volumn 38, Issue 2, 2010, Pages 602-610

  Tanaka, M ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

Diabetic nephropathy; L N type calcium channel blocker; Sympathetic nervous activity; Urinary albumin

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; MANIDIPINE; MEPIRODIPINE; NIFEDIPINE;

ADRENERGIC ACTIVITY; ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLUSHING; HEART RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRURITUS; RENAL PROTECTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 77953709427     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800222     Document Type: Article

References (30)

1. Ruggenenti P, Fassi A, Ilieva AP, et al for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
2. Lewis El, Hunsicker LG, Clarke WR, et al Renoprotective effect of the angiotensin-recepior antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
3. Viberti G, Wheeldon NM, for the Micro-Albuminuria Reduction with VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
4. Konno Y, Kimura K: Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J 2008; 49: 723-732.
5. Konda T, Enomoto A, Matsushita J, et al The N-and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101: 1-13.
6. Morimoto S, Yano Y, Maki K, et al: Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens 2007; 25: 2178-2183.
7. Fujita T, Ando K, Nishimura H, et al. for the Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-1549.
8. Rose GW, Kanno Y, Ikebukuro H, et al: Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24: 377-383.
9. Katayama K, Nomura S, Ishikawa H, et al: Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo-and microalbuminuria. Kidney Int 2006; 70:151-156.
10. Tsuchihashi T, Ueno M, Tominaga M, et al: Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005;27:583-591.
11. Ogihara T, Kikuchi K, Matsuoka H, et al. for the Japanese Society of Hypertension Committee: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
12. Sakata K, Shirotani M, Yoshida H, et al Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999; 33: 1447-1452.
13. Hoshide S, Kario K, Ishikawa J, et al: Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res 2005; 28: 1003-1008.
14. Okamura T, Hayakawa T, Kadowaki T, et al: Resting heart rate and cause-specific death in a 16.5-year cohort study of the Japanese general population. Am Heart J 2004; 147: 1024-1032.
15. Hozawa A, Ohkubo T, Kikuya M, et al: Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens 2004; 17: 1005-1010.
16. Gillman MW, Kannel WB, Belanger A, et al Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154.
17. Yuyun MF, Khaw KT, Luben R, et al: A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004; 159: 284-293.
18. Adler AI, Stevens RJ, Manley SE, et al: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
19. Ibsen H, Olsen MH, Wachtell K, et al Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
20. Hillege HL, Fidler V, Diercks GF, et al. for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
21. Arnlov J, Evans JC, Meigs JB, et al: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-975.
22. Uchino K, Nishikimi T, Frohlich ED: Alpha 1-adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR. Am I Physiol 1991; 261: R576-R580.
23. 1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation. Hypertens Res 2004; 27: 509-515.
24. Amann K, Rump LC, Simonaviciene A, et al: Effects of low dose sympathetic inhibition onglomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-1478.
25. Krespi PG, Makris TK, Hatzizacharias AN, et al: Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12: 463-467.
26. Neumann J, Ligtenberg G, Klein IH, et al: Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49: 506-510.
27. Mena-Martín FJ, Martín-Escudero JC, Simal-Blanco F, et al: Influence of sympathetic activity on blood pressure and vascular damage evaluated by means of urinary albumin excretion. J Clin Hypertension 2006; 8:619-624.
28. Huggett RJ, Scott EM, Gilbey SG, et al Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101.
29. Wu JS, Yang YC, Lin TS, et al: Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab 2007; 92: 3885-3889.
30. Zhou X, Ono H, Ono Y, et al: N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an 1-NAMEJSHR model. J Hypertens 2002; 20: 993-1000.